Monday, December 23, 2024
HomeTagsSPEXIS AG

SPEXIS AG

Spexis’ CXCR4 Inhibitor Balixafortide Demonstrates Synergistic Efficacy in Combination With Docetaxel in a Metastatic Prostate Cancer Preclinical Model

SPEXIS AG, a clinical-stage biopharmaceutical company, announced that its CXCR4 inhibitor balixafortide demonstrated synergistic efficacy in combination with docetaxel compared to either drug alone...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics